Enhanced antitumor activity of adriamycin in combination with allopurinol.
Xanthine oxidase reduction of adriamycin (Am) and daunorubicin (Dm) to their respective 7-deoxy aglycones is inhibited by allopurinol. Administered to DBA/2 mice with L1210 leukemia, allopurinol (60 mg/kg per day X 3) enhances the antitumor activity of adriamycin.
D000493:Allopurinol / Q000008:administration & dosage*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage / Q000378:metabolism; D004317:Doxorubicin / Q000008:administration & dosage* / Q000378:metabolism; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000201:enzymology; D051379:Mice; D008811:Mice, Inbred DBA; D010084:Oxidation-Reduction; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
D000493:Allopurinol; D004317:Doxorubicin; D014969:Xanthine Oxidase; D003630:Daunorubicin